Elite Repair Stack across Europe

The Elite Repair Stack puts our BPC-157 & TB-500 pen next to our GHK-CU 50 pen. These three molecules sit together because all of them are discussed in the language of repair: two in tendon, ligament and muscle models, one in collagen synthesis and wound closure. What they do not share is an evidence base.

Two pens, three molecules

The first pen holds BPC-157 and TB-500 together; the second holds the copper complex of the tripeptide GHK. Across the two pens nothing is mixed or co-formulated: each is the product listed on its own page, and how you might combine or sequence them is not something we advise on. Background is at what is BPC-157 & TB-500? and what is GHK-Cu?.

The soft-tissue pair: a large literature, almost all preclinical

BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice, first described by Sikiric and colleagues in 1993. The preclinical work since is genuinely large, covering tendon, ligament, muscle, bone and gastrointestinal models, with reported effects on angiogenesis, collagen synthesis and fibroblast activity. Development reviews are blunt about where that leaves it: no approved formulation, no validated dosing regimen and no completed Phase II trial; human exposure has been limited to safety trials, including a programme in inflammatory bowel disease under the code PL14736. Analyses by author affiliation also attribute more than eighty per cent of published BPC-157 studies to a single group at the University of Zagreb. That cuts both ways: it weakens the efficacy case, and it weakens any claim that adverse effects have been ruled out. Mateescu DM et al. BPC-157 as an Investigational Peptide Therapeutic. Pharmaceutics 2026. PMID 42198317; Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949; Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals 2025. PMID 40005999

TB-500 is the other half of that pen, a name used for thymosin beta-4, the naturally occurring 43-amino-acid protein, and for fragments of it. Thymosin beta-4 itself has been through registered human trials, but read the route carefully: a Phase II in moderate-to-severe dry eye that randomised 72 subjects to 0.1% ophthalmic solution or placebo over 28 days, and a placebo-controlled dose-response study in venous stasis ulcers. Those are topical and ophthalmic studies, not trials of systemic injection for tendon, ligament or muscle repair. Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial. Clin Ophthalmol 2015. PMID 26056426; ClinicalTrials.gov NCT01387347; ClinicalTrials.gov NCT00832091

The pairing rationale is mechanistic: BPC-157 studied mostly in localised repair models, thymosin beta-4 in cell migration and wound response. No published human trial has administered the two together and measured the result. How they differ is set out at BPC-157 vs TB-500.

The copper tripeptide: human data that is mostly topical

GHK is glycyl-L-histidyl-L-lysine, a three-amino-acid peptide that binds copper(II) as a defined 1:1 complex. Pickart isolated it from human albumin in 1973; it occurs naturally in plasma, and reported levels fall from around 200 ng/ml at 20 to roughly 80 ng/ml by 60. The best-characterised laboratory finding is stimulation of collagen synthesis in fibroblast culture, beginning between 10⁻¹² and 10⁻¹¹ M and peaking around 10⁻⁹ M; reviews describe the peptide modulating both synthesis and breakdown of collagen and glycosaminoglycans. Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu. FEBS Lett 1988. PMID 3169264; Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008. PMID 18644225; Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730

The human work is where GHK-Cu differs most from the pen beside it. Some of it is controlled: a multicentre, randomised, evaluator-blinded, placebo-controlled study of a GHK-copper gel on diabetic neuropathic ulcers reported faster closure than vehicle. But that trial studied a gel on a wound, and the rest of the human record is topical skincare. GHK-Cu in an injectable pen is a different product with a different evidence base from GHK-Cu in a cream or a wound gel, because the complex’s behaviour depends on pH, concentration, counter-ions and the rest of the formulation. We set that out at GHK-Cu injectable vs topical copper peptides. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen 1994. PMID 17147644

Where the evidence for the set stops

Molecule	Evidence base	Human trials of injection for repair
BPC-157	Preclinical, one dominant group; human safety trials only	None completed
Thymosin beta-4	Topical and ophthalmic Phase II	None
GHK-Cu	Cell culture, topical skincare, one wound-gel trial	None

No published trial has tested these pens together, and none of the three molecules holds a marketing authorisation as a medicine. The reasons for grouping them are mechanistic; the outcome of the set in a person has not been measured. What we can show is what each pen contains. An independent laboratory tests every batch for identity by mass spectrometry, purity by HPLC and sterility; the certificate for your lot is reachable from the QR code on the pen or from /coa.

Who typically chooses this set

This is the set you pick when the goal you are looking at is recovery and you also want the compound most associated with collagen and skin. The combined pen holds both soft-tissue molecules in one cartridge; GHK-Cu adds the tripeptide whose laboratory data sits on the collagen side. If GHK-Cu interests you and the repair pen does not, the Vitality Stack keeps GHK-Cu and pairs it with NAD+ instead, a set chosen for ageing and skin rather than repair. Both pens ship together under one cold chain from inside the EU.